JP2016532647A5 - - Google Patents

Download PDF

Info

Publication number
JP2016532647A5
JP2016532647A5 JP2016520627A JP2016520627A JP2016532647A5 JP 2016532647 A5 JP2016532647 A5 JP 2016532647A5 JP 2016520627 A JP2016520627 A JP 2016520627A JP 2016520627 A JP2016520627 A JP 2016520627A JP 2016532647 A5 JP2016532647 A5 JP 2016532647A5
Authority
JP
Japan
Prior art keywords
pharmaceutically acceptable
acceptable salt
compound according
methyl
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2016520627A
Other languages
English (en)
Japanese (ja)
Other versions
JP6348582B2 (ja
JP2016532647A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2014/064836 external-priority patent/WO2015052610A1/en
Publication of JP2016532647A publication Critical patent/JP2016532647A/ja
Publication of JP2016532647A5 publication Critical patent/JP2016532647A5/ja
Application granted granted Critical
Publication of JP6348582B2 publication Critical patent/JP6348582B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2016520627A 2013-10-09 2014-09-25 プロスタグランジンep3受容体の拮抗薬 Expired - Fee Related JP6348582B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361888822P 2013-10-09 2013-10-09
US61/888,822 2013-10-09
PCT/IB2014/064836 WO2015052610A1 (en) 2013-10-09 2014-09-25 Antagonists of prostaglandin ep3 receptor

Publications (3)

Publication Number Publication Date
JP2016532647A JP2016532647A (ja) 2016-10-20
JP2016532647A5 true JP2016532647A5 (enExample) 2017-10-26
JP6348582B2 JP6348582B2 (ja) 2018-06-27

Family

ID=51900918

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016520627A Expired - Fee Related JP6348582B2 (ja) 2013-10-09 2014-09-25 プロスタグランジンep3受容体の拮抗薬

Country Status (9)

Country Link
US (1) US9278953B2 (enExample)
EP (1) EP3055300B1 (enExample)
JP (1) JP6348582B2 (enExample)
AR (1) AR097963A1 (enExample)
CA (1) CA2926568C (enExample)
ES (1) ES2665153T3 (enExample)
TW (1) TW201527297A (enExample)
UY (1) UY35776A (enExample)
WO (1) WO2015052610A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016103097A1 (en) * 2014-12-22 2016-06-30 Pfizer Inc. Antagonists of prostaglandin ep3 receptor
US10336701B2 (en) 2017-08-10 2019-07-02 Janssen Pharmaceutica Nv Pyridin-2-one derivatives of formula (II) useful as EP3 receptor antagonists
US10590083B2 (en) 2017-08-10 2020-03-17 Janssen Pharmaceutica Nv Pyridin-2-one derivatives of formula (I) useful as EP3 receptor antagonists
US10399944B2 (en) 2017-08-10 2019-09-03 Janssen Pharmaceutica Nv Pyridin-2-one derivatives of formula (III) useful as EP3 receptor antagonists
JOP20200294A1 (ar) 2018-05-17 2020-11-17 Bayer Ag مشتقات ثنائي هيدروبيرازولو بيرازين كربوكساميد تحمل بدائل
WO2021094208A1 (en) 2019-11-12 2021-05-20 Bayer Aktiengesellschaft Substituted imidazo pyrimidine ep3 antagonists
WO2021094209A1 (en) 2019-11-12 2021-05-20 Bayer Aktiengesellschaft Substituted pyrrolo triazine carboxamide derivatives as prostaglandin ep3 receptor antagonists
WO2021094210A1 (en) 2019-11-12 2021-05-20 Bayer Aktiengesellschaft Substituted pyrazine carboxamide derivatives as prostaglandin ep3 receptor antagonists
IL307374A (en) 2021-04-07 2023-11-01 Hadasit Med Res Service EP3 antagonists for the treatment of diabetes

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0028489B1 (en) 1979-11-05 1983-10-05 Beecham Group Plc Enzyme derivatives, and their preparation
US5612359A (en) 1994-08-26 1997-03-18 Bristol-Myers Squibb Company Substituted biphenyl isoxazole sulfonamides
TW536540B (en) 1997-01-30 2003-06-11 Bristol Myers Squibb Co Endothelin antagonists: N-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-4-(2-oxazolyl)[1,1'-biphenyl]-2-yl]methyl]-N,3,3-trimethylbutanamide and N-(4,5-dimethyl-3-isoxazolyl)-2'-[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl]-4'-(2-oxazolyl)[1,1'-biphe
ES2318899T3 (es) 1998-07-06 2009-05-01 Bristol-Myers Squibb Company Bifenil sulfonamidas como antagonistas duales de los receptores de angiotensina y endotelina.
MY125533A (en) 1999-12-06 2006-08-30 Bristol Myers Squibb Co Heterocyclic dihydropyrimidine compounds
KR20030076716A (ko) 2001-02-28 2003-09-26 머크 앤드 캄파니 인코포레이티드 멜라노코르틴-4 수용체 효능제로서 아실화 피페리딘 유도체
EP1478437B1 (en) 2002-02-27 2005-08-31 Pfizer Products Inc. Acc inhibitors
DE602005015699D1 (de) 2004-05-12 2009-09-10 Pfizer Prod Inc Prolinderivate und deren verwendung als dipeptidylpeptidase-iv-inhibitoren
JP4069159B2 (ja) 2004-05-25 2008-04-02 ファイザー・プロダクツ・インク テトラアザベンゾ[e]アズレン誘導体及びそれらのアナログ
PA8660701A1 (es) 2005-02-04 2006-09-22 Pfizer Prod Inc Agonistas de pyy y sus usos
US20080200568A1 (en) 2005-08-30 2008-08-21 Stephanie Chissoe Genes Associated With Type ll Diabetes Mellitus
PL2463283T3 (pl) 2006-04-20 2014-10-31 Pfizer Prod Inc Skondensowane fenyloamidowe związki heterocykliczne do zapobiegania i leczenia chorób pośredniczonych przez glukokinazę
KR20090083956A (ko) 2006-11-29 2009-08-04 화이자 프로덕츠 인크. 스피로케톤 아세틸-CoA 카르복실라제 억제제
US20090036425A1 (en) 2007-08-02 2009-02-05 Pfizer Inc Substituted bicyclolactam compounds
JP5435592B2 (ja) 2008-05-28 2014-03-05 ファイザー・インク ピラゾロスピロケトンアセチルCoAカルボキシラーゼ阻害剤
JP2011521940A (ja) 2008-05-28 2011-07-28 ファイザー・インク ピラゾロスピロケトンアセチルCoAカルボキシラーゼ阻害剤
CA2729581A1 (en) 2008-07-29 2010-02-04 Pfizer Inc. Fluorinated heteroaryls
WO2010023594A1 (en) 2008-08-28 2010-03-04 Pfizer Inc. Dioxa-bicyclo[3.2.1.]octane-2,3,4-triol derivatives
TW201038580A (en) 2009-02-02 2010-11-01 Pfizer 4-amino-5-oxo-7,8-dihydropyrimido[5,4-f][1,4]oxazepin-6(5H)-yl)phenyl derivatives
UA99882C2 (uk) 2009-03-11 2012-10-10 Пфайзер Інк. Похідні бензофуранілу, фармацевтична композиція та спосіб лікування захворювань (варіанти)
CA2754685A1 (en) 2009-03-11 2010-09-16 Pfizer Inc. Substituted indazole amides
EP2408780A2 (en) 2009-03-20 2012-01-25 Pfizer Inc. 3-oxa-7-azabicycloý3.3.1¨nonanes
WO2010128414A1 (en) 2009-05-08 2010-11-11 Pfizer Inc. Gpr 119 modulators
JP2012526097A (ja) 2009-05-08 2012-10-25 ファイザー・インク Gpr119調節因子
KR20120061063A (ko) 2009-06-05 2012-06-12 화이자 인코포레이티드 Gpr 119 조절제로서의 l-(피페리딘-4-일)-피라졸 유도체
WO2011005611A1 (en) 2009-07-09 2011-01-13 Merck Sharp & Dohme Corp. Neuromedin u receptor agonists and uses thereof

Similar Documents

Publication Publication Date Title
JP2016532647A5 (enExample)
JP2017071634A5 (enExample)
JP2018514518A5 (enExample)
JP2017520613A5 (enExample)
JP2017509586A5 (enExample)
JP2016518328A5 (enExample)
JP2016523269A5 (enExample)
JP2017105793A5 (enExample)
JP2016523270A5 (enExample)
JP2019524883A5 (enExample)
CY1119487T1 (el) Αναστολεις κιναζολινης των ενεργοποιητικων μεταλλαγμενων μορφων του υποδοχεα του επιδερμικου αυξητικου παραγοντα
CY1119231T1 (el) Θειαδιαζολιδινοδιονες ως αναστολεις της gsk-3
WO2016205475A3 (en) Tgr5 modulators and methods of use thereof
JP2016505010A5 (enExample)
JP2017517512A5 (enExample)
JP2012092103A5 (enExample)
TR201904658T4 (tr) Bisiklik füzyonla birleştirilmiş heteroaril veya aril bileşikleri ve bunların ırak4 inhibitörleri olarak kullanımları.
JP2013502431A5 (enExample)
JP2016530259A5 (enExample)
JO3377B1 (ar) مشتقات بيريدينيل وبيريدينيل مندمج
WO2016098054A9 (en) Processes for preparing oxathiazin-like compounds
JP2016505637A5 (enExample)
JP2015504909A5 (enExample)
JP2018521020A5 (enExample)
JP2016510326A5 (enExample)